Detailed information for compound 2074475

Basic information

Technical information
  • Name: Unnamed compound
  • MW: 410.417 | Formula: C22H20F2N4O2
  • H donors: 1 H acceptors: 4 LogP: 3.17 Rotable bonds: 7
    Rule of 5 violations (Lipinski): 1
  • SMILES: O=C([C@@H]1C[C@@]1(COc1cnc(nc1C)C)c1cccc(c1)F)Nc1ccc(cn1)F
  • InChi: 1S/C22H20F2N4O2/c1-13-19(11-25-14(2)27-13)30-12-22(15-4-3-5-16(23)8-15)9-18(22)21(29)28-20-7-6-17(24)10-26-20/h3-8,10-11,18H,9,12H2,1-2H3,(H,26,28,29)/t18-,22+/m0/s1
  • InChiKey: MUGXRYIUWFITCP-PGRDOPGGSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

No synonyms found for this compound

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens hypocretin (orexin) receptor 1 Starlite/ChEMBL References
Homo sapiens potassium voltage-gated channel, subfamily H (eag-related), member 2 Starlite/ChEMBL References
Homo sapiens hypocretin (orexin) receptor 2 Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
Species Potential target Known druggable target/s Ortholog Group
Brugia malayi Voltage-gated potassium channel, HERG (KCNH2)-related. C. elegans unc-103 ortholog Get druggable targets OG5_128858 All targets in OG5_128858
Loa Loa (eye worm) hypothetical protein Get druggable targets OG5_128858 All targets in OG5_128858
Echinococcus multilocularis G protein coupled receptor 139 Get druggable targets OG5_127863 All targets in OG5_127863
Echinococcus multilocularis potassium voltage gated channel subfamily H Get druggable targets OG5_128858 All targets in OG5_128858
Echinococcus multilocularis neuropeptide receptor Get druggable targets OG5_127863 All targets in OG5_127863
Echinococcus granulosus neuropeptide receptor Get druggable targets OG5_127863 All targets in OG5_127863
Trichomonas vaginalis voltage and ligand gated potassium channel, putative Get druggable targets OG5_128858 All targets in OG5_128858
Schistosoma mansoni neuropeptide receptor Get druggable targets OG5_127863 All targets in OG5_127863
Schistosoma japonicum ko:K04910 potassium voltage-gated channel, Eag-related subfamily H, member 7, putative Get druggable targets OG5_128858 All targets in OG5_128858
Loa Loa (eye worm) voltage and ligand gated potassium channel Get druggable targets OG5_128858 All targets in OG5_128858
Schistosoma japonicum ko:K04910 potassium voltage-gated channel, Eag-related subfamily H, member 7, putative Get druggable targets OG5_128858 All targets in OG5_128858
Echinococcus granulosus potassium voltage gated channel subfamily H Get druggable targets OG5_128858 All targets in OG5_128858
Schistosoma mansoni voltage-gated potassium channel Get druggable targets OG5_128858 All targets in OG5_128858
Schistosoma japonicum ko:K04209 neuropeptide Y receptor, invertebrate, putative Get druggable targets OG5_127863 All targets in OG5_127863
Trichomonas vaginalis voltage and ligand gated potassium channel, putative Get druggable targets OG5_128858 All targets in OG5_128858
Schistosoma mansoni voltage-gated potassium channel Get druggable targets OG5_128858 All targets in OG5_128858
Schistosoma japonicum Potassium voltage-gated channel subfamily H member 2, putative Get druggable targets OG5_128858 All targets in OG5_128858
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Echinococcus granulosus sex peptide receptor hypocretin (orexin) receptor 1 425 aa 350 aa 23.4 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Toxoplasma gondii acetyl-CoA carboxylase ACC1 0.0392 1 1
Mycobacterium ulcerans pyruvate carboxylase 0.0149 0.3075 1
Schistosoma mansoni acetyl-CoA carboxylase 0.0392 1 1
Leishmania major acetyl-CoA carboxylase, putative 0.0392 1 1
Loa Loa (eye worm) carboxyl transferase domain-containing protein 0.0379 0.9608 1
Trypanosoma brucei unspecified product 0.0098 0.1615 0.1329
Trypanosoma brucei acetyl-CoA carboxylase 0.0392 1 1
Mycobacterium leprae Probable bifunctional protein acetyl-/propionyl-coenzyme A carboxylase, alpha chain AccA3 (BccP) 0.0149 0.3075 1
Chlamydia trachomatis biotin carboxylase 0.0136 0.2683 1
Echinococcus granulosus neuropeptide receptor 0.0128 0.247 0.2406
Entamoeba histolytica acetyl-coA carboxylase, putative 0.0067 0.0721 0.5
Trichomonas vaginalis voltage and ligand gated potassium channel, putative 0.0042 0 0.5
Trypanosoma cruzi acetyl-CoA carboxylase 0.0243 0.5739 1
Echinococcus multilocularis neuropeptide receptor 0.0128 0.247 0.2406
Plasmodium vivax biotin carboxylase subunit of acetyl CoA carboxylase, putative 0.0284 0.6909 0.5
Mycobacterium ulcerans bifunctional protein acetyl-/propionyl-coenzyme a carboxylase (alpha chain) AccA3 0.0149 0.3075 1
Giardia lamblia Acetyl-CoA carboxylase/pyruvate carboxylase fusion protein, putative 0.0067 0.0721 0.5
Trichomonas vaginalis voltage and ligand gated potassium channel, putative 0.0042 0 0.5
Plasmodium falciparum biotin carboxylase subunit of acetyl CoA carboxylase, putative 0.0284 0.6909 0.5
Trypanosoma brucei 3-methylcrotonyl-CoA carboxylase alpha subunit, putative 0.0149 0.3075 0.2839
Schistosoma mansoni methylcrotonyl-CoA carboxylase 0.0149 0.3075 0.2933
Toxoplasma gondii acetyl-coA carboxylase ACC2 0.0392 1 1
Mycobacterium ulcerans acetyl-/propionyl-coenzyme a carboxylase alpha chain AccA1 0.0149 0.3075 1
Echinococcus granulosus propionyl coenzyme A carboxylase beta chain 0.0053 0.033 0.0248
Toxoplasma gondii pyruvate carboxylase 0.0149 0.3075 0.2839
Echinococcus multilocularis propionyl coenzyme A carboxylase beta chain 0.0053 0.033 0.0248
Mycobacterium tuberculosis Probable pyruvate carboxylase Pca (pyruvic carboxylase) 0.0149 0.3075 1
Wolbachia endosymbiont of Brugia malayi Acetyl/propionyl-CoA carboxylase, alpha subunit 0.0149 0.3075 1
Mycobacterium ulcerans acetyl-/propionyl-coenzyme a carboxylase alpha chain, AccA2 0.0149 0.3075 1
Schistosoma mansoni neuropeptide receptor 0.0128 0.247 0.2316
Trypanosoma cruzi 3-methylcrotonyl-CoA carboxylase, putative 0.0149 0.3075 0.5074
Leishmania major carboxylase, putative 0.0149 0.3075 0.2839
Echinococcus granulosus propionyl coenzyme A carboxylase alpha chain 0.0149 0.3075 0.3016
Echinococcus multilocularis acetyl coenzyme A carboxylase 1 0.0392 1 1
Leishmania major methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein 0.0149 0.3075 0.2839
Trypanosoma brucei 3-methylcrotonyl-CoA carboxylase alpha subunit, putative 0.0149 0.3075 0.2839
Echinococcus multilocularis G protein coupled receptor 139 0.0128 0.247 0.2406
Schistosoma mansoni methylcrotonyl-CoA carboxylase 0.0149 0.3075 0.2933
Brugia malayi Carboxyl transferase domain containing protein 0.0379 0.9608 1
Schistosoma mansoni propionyl-CoA carboxylase beta chain mitochondrial precursor 0.0053 0.033 0.0132
Schistosoma mansoni pyruvate carboxylase 0.0149 0.3075 0.2933
Mycobacterium tuberculosis Probable acetyl-/propionyl-coenzyme A carboxylase alpha chain (alpha subunit) AccA2: biotin carboxylase + biotin carboxyl carrie 0.0149 0.3075 1
Echinococcus multilocularis propionyl coenzyme A carboxylase alpha chain 0.0149 0.3075 0.3016
Trypanosoma cruzi 3-methylcrotonyl-CoA carboxylase, putative 0.0149 0.3075 0.5074

Activities

Activity type Activity value Assay description Source Reference
IC50 (binding) = 6.1 uM Inhibition of human ERG ChEMBL. 25953512
IC50 (ADMET) > 20 uM Inhibition of CYP1A2 in human liver microsomes using phenacetin as susbtrate incubated for 30 mins prior to substrate addition for 10 mins by LC-MS/MS analysis ChEMBL. 25953512
IC50 (ADMET) > 20 uM Inhibition of CYP2C8 in human liver microsomes using rosiglitazone as susbtrate incubated for 30 mins prior to substrate addition for 10 mins by LC-MS/MS analysis ChEMBL. 25953512
IC50 (ADMET) > 20 uM Inhibition of CYP2C9 in human liver microsomes using tolbutamide as susbtrate incubated for 30 mins prior to substrate addition for 10 mins by LC-MS/MS analysis ChEMBL. 25953512
IC50 (ADMET) > 20 uM Inhibition of CYP2C19 in human liver microsomes using S-mephenytoin as susbtrate incubated for 30 mins prior to substrate addition for 10 mins by LC-MS/MS analysis ChEMBL. 25953512
IC50 (ADMET) > 20 uM Inhibition of CYP2D6 in human liver microsomes using bufuralol as susbtrate incubated for 30 mins prior to substrate addition for 10 mins by LC-MS/MS analysis ChEMBL. 25953512
Ki (binding) = 0.44 nM Binding affinity to human OX2R expressed in HEK-293 cells assessed as inhibition of orexin A-induced calcium accumulation by FLIPR assay ChEMBL. 25953512
Ki (binding) = 3 nM Binding affinity to human OX2R by radioligand displacement binding assay ChEMBL. 25953512
Ki (binding) = 5.7 nM Binding affinity to human OX1R expressed in HEK-293 cells assessed as inhibition of orexin A-induced calcium accumulation by FLIPR assay ChEMBL. 25953512
Ki (binding) = 6 nM Binding affinity to human OX1R by radioligand displacement binding assay ChEMBL. 25953512
Stabilty (ADMET) = 90 % Metabolic stability in human liver microsomes assessed as residual ratio at 0.1 uM after 15 mins by LC-MS analysis ChEMBL. 25953512
Time (functional) = 75.3 min Sleep promoting activity in C57BL/6NCrlCrlj mouse assessed as reduction in wakefulness time at 30 mg/kg, po administered immediately prior to beginning of dark cycle measured during first 3 hrs after drug administration by electroencephalogram/electromyogram analysis (Rvb = 116.7 min) ChEMBL. 25953512

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.